Evaluating minority representation across health care settings in hidradenitis suppurativa and psoriasis.
Int J Womens Dermatol
; 10(1): e129, 2024 Mar.
Article
in En
| MEDLINE
| ID: mdl-38240009
ABSTRACT
Background:
Females and minorities have been underrepresented in clinical research despite legislative efforts, including in hidradenitis suppurativa (HS) and psoriasis (PsO) clinical trials.Objective:
To identify differences in demographic breakdowns of HS and PsO patients between health care settings to uncover any causative health disparities.Methods:
This study reports racial, ethnic, and sex of HS and PsO patient populations across the emergency department (ED), inpatient, clinical trial, and registry settings. In addition, 95% confidence intervals are used as proxies of statistical significance to compare demographics between settings.Results:
Female, Hispanic, and Black patients were underrepresented in HS clinical trials compared to their population prevalence (female 63.7% vs 73.5%; Hispanic 3.8% vs 12.0%; Black 9.1% vs 20.3%). Female and Black patients were underrepresented in PsO trials compared to their population prevalence (female 33.0% vs 54.8%; Black 2.2% vs 5.7%). Black patients were overrepresented in the inpatient and ED settings in HS (inpatient vs ED vs population prevalence 49.9% vs 49.9% vs 20.3%) and in the inpatient setting in PsO (inpatient vs population prevalence 19.8% vs 5.7%).Limitations:
The main limitation is the reliability and generalizability of the published studies used to compare demographics across settings.Conclusion:
Underrepresentation of females and minorities in HS and PsO clinical trials is consistent with published literature. Overrepresentation of Black patients in acute care settings is likely multifactorial.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Risk_factors_studies
Aspects:
Equity_inequality
Language:
En
Journal:
Int J Womens Dermatol
Year:
2024
Document type:
Article
Country of publication:
United States